MetaCap

Arbutus Biopharma (ABUS) vs Sagimet Biosciences Series A (SGMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sagimet Biosciences Series A (SGMT) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 36.1% versus a loss of 6.7%. Sagimet Biosciences Series A is the larger company by market cap ($648.0 million vs $616.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABUS-6.73%SGMT+36.13%
+76%+20%-37%
Nov 21, 20251 yearNov 20, 2026
ABUS+80.27%SGMT-43.07%
+145%+23%-98%
Jul 10, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABUS versus SGMT key metrics
MetricABUSSGMT
Share price$4.02$9.08
Market cap$616.24M$648.02M
1-day change-1.23%-5.61%
YTD return-16.42%+53.38%
1-year return-6.73%+36.13%
5-year return+28.43%—
P/E ratio (TTM)3.59—
EPS (TTM)$1.12$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.08M—
Revenue growth (YoY)+128.21%—
Net income (latest FY)$-33.50M$-51.04M
Operating margin-270.96%—
Net margin-237.88%—
52-week high$5.45$11.45
52-week low$3.50$4.50
Distance from 52-week high-26.24%-20.69%
Analyst consensusnonestrong_buy
Avg. price target upside+32.34%+200.33%
Average volume4.98M1.23M
Shares outstanding153.29M71.37M
Employees1916
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SGMT has outperformed ABUS by 42.9 percentage points over the past year.

About Arbutus Biopharma

ABUS stock →

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Sagimet Biosciences Series A

SGMT stock →

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

ABUS vs SGMT FAQ

Which is bigger, Arbutus Biopharma or Sagimet Biosciences Series A?

Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $648.02M compared with $616.24M for Arbutus Biopharma (ABUS).

Which stock has performed better over the past year, ABUS or SGMT?

SGMT returned +36.13% over the past 12 months, compared with -6.73% for ABUS (price return, excluding dividends). Past performance does not predict future results.

Are Arbutus Biopharma and Sagimet Biosciences Series A in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons